Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
Advertisement
Dynavax Technologies Corporation announced that the U.S. Patent Office has issued the company a broad composition of matter patent covering the company's proprietary second-generation TLR9 agonists.
The claims cover a broad class of novel TLR9 agonists containing short DNA sequences separated by spacer molecules. These linear chimeric immunomodulatory compounds (CICs), are being developed at Dynavax for application across a wide range of therapeutic categories. The claims cover CICs with or without antigen, and alone or in a pharmaceutical preparation. The current term for this patent expires in June 2022. The patent, U.S. patent No. 7,255,868 B2, was issued August 14, 2007 with inventors Karen Fearon, Dino Dina, M.D., and Stephen Tuck.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Dynavax Appoints Francis R. Cano, Ph.D. to Board of Directors
'Jumping genes' create antibiotic resistance - 'Jumping genes' find gaps in DNA, cause widespread antibiotic resistance in bacteria, study finds
Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform - Expansion of senior team to focus on drug discovery and development
INTEGRA Biosciences announced strong end of year sales of over Euro 5 million - Well positioned for growth in 2004
Major Plant Research Company Takes World-Wide License to Genomatix´ Regulatory Sequence Analysis Application
Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH
